News Search Results
Dec 08, 2025, 10:00 ET Carolyn Bertozzi returns to Lilly board of directors
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Dec 08, 2025, 09:06 ET Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025
biomarkers, and measuring quality of life using patient-reported outcome tools.About Halia TherapeuticsHalia Therapeutics is a biotechnology company developing first-in-class inflammasome inhibitors. We target the root causes of inflammation-driven diseases to create transformative therapies.
More news about: Halia Therapeutics
Dec 08, 2025, 09:00 ET The Galien Foundation Honors 2025 Prix Galien Bridges Awards Recipients
Medical Students' Union House. The Foundation honored this year's award winners in the following categories: "Best Bridge-Builder Institution," "Best Biotechnology and Pharmaceutical Product," "Best Medical Technology/AI Advances in Human Health," "Best Product for Rare/Orphan Diseases," and "Best Public Sector
More news about: The Galien Foundation
Dec 08, 2025, 08:38 ET OODA AI: Actionable Intelligence Powered by Advanced Retrieval-Augmented Generation
across the entire corpus of OODA content, including long-form research and analysis on artificial intelligence, cybersecurity, energy technology, biotechnology, defense innovation, disruptive technology companies, and geopolitical risk. By combining state-of-the-art AI summarization with
More news about: OODA LLC
Dec 08, 2025, 08:34 ET GlycoNex Signs CDMO Service Agreement with Change Cure to Advance HMGB1-Targeted Antibody Program
GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced that it has entered into a CDMO service agreement
More news about: GlycoNex, Inc.
Dec 08, 2025, 08:00 ET Ouro Medicines Receives U.S. FDA Orphan Drug Designation for Gamgertamig (OM336) for Immune Thrombocytopenia
SOUTH SAN FRANCISCO, Calif., Dec. 8, 2025 /PRNewswire/ -- Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic, immune-mediated diseases, today announced that gamgertamig (OM336),
More news about: Ouro Medicines
Dec 08, 2025, 08:00 ET Andelyn Biosciences Announces Partnership with Jaguar Gene Therapy to Provide Late-Stage PPQ Manufacturing
LinkedIn.About Jaguar Gene TherapyJaguar Gene Therapy, LLC is a clinical-stage biotechnology company dedicated to accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases including those that impact
More news about: Andelyn Biosciences
Dec 08, 2025, 07:00 ET HanchorBio Presents First-in-Human Data of HCB101 Monotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma at ASH 2025
and SAN FRANCISCO, Dec. 8, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today presented new first-in-human data from its ongoing
More news about: HanchorBio Inc.
Dec 08, 2025, 06:00 ET Oppenheimer & Co. Inc. Strengthens Equities and Biotech Research Teams with Addition of Kostas Biliouris, Ph.D.
experience and perspective and we are thrilled to have him onboard."Oppenheimer provides coverage across the healthcare ecosystem, including biotechnology, pharmaceuticals, medical technology, and related sectors. The healthcare franchise has long been one of the firm's most established areas of expertise."I
More news about: Oppenheimer & Co. Inc.
Dec 08, 2025, 05:35 ET Exosomes Market Led by North America with 53% Revenue Share and Global Market Size Set to Surpass USD 2B by 2030, Says Mordor Intelligence
collaborations between biotechnology companies and academic research centers. The region benefits from supportive regulatory pathways and high adoption of advanced biomedical technologies. Asia-Pacific is projected to record the fastest growth, supported by expanding biotechnology infrastructure, increasing
More news about: Mordor Intelligence Private Limited
Dec 08, 2025, 04:40 ET Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight
(via steps at 1 mg, 2 mg, 5 mg, 10 mg, 20 mg and 40 mg).About Ascletis Pharma Inc.Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Dec 08, 2025, 00:00 ET AsymBio Commences Commercial Operations at Fengxian Base, Strengthening Global Biopharmaceutical CDMO Capabilities
https://www.prnewswire.com/news-releases/asymbio-commences-commercial-operations-at-fengxian-base-strengthening-global-biopharmaceutical-cdmo-capabilities-302634986.htmlSOURCE Shanghai Asymchem Biotechnology Co., Ltd.
More news about: Shanghai Asymchem Biotechnology Co., Ltd.
Dec 07, 2025, 21:00 ET Median PFS Trending Beyond One Year: Leads Biolabs' LBL-034 Showcases Breakthrough Clinical Data in Oral Presentation at the 2025 ASH Annual Meeting
from the U.S. FDA for the treatment of multiple myeloma.About Leads BiolabsFounded in 2012, Leads Biolabs is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies to address underserved medical needs in oncology,
More news about: Leads Biolabs
Dec 07, 2025, 20:57 ET IASO Bio Presents Updated Results for Equecabtagene Autoleucel in High-Risk Newly Diagnosed Multiple Myeloma Patients at 2025 ASH
SHANGHAI and NANJING, China and PLEASANTON, Calif., Dec. 7, 2025 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceutical company focused on the discovery, development, manufacturing,
More news about: IASO Bio
Dec 07, 2025, 16:30 ET Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Dec 07, 2025, 12:01 ET Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years
enables us to identify, develop, and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit
More news about: CSL
Dec 07, 2025, 09:30 ET Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition
Calif., Dec. 7, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced updated data from its ongoing Phase 1b study evaluating R2891, an
More news about: Rigel Pharmaceuticals, Inc.
Dec 07, 2025, 08:00 ET Orna Therapeutics Presents New Data Supporting its in vivo CAR Programs for Autoimmune Diseases and Oncology at the 67th American Society of Hematology Annual Meeting
WATERTOWN, Mass., Dec. 7, 2025 /PRNewswire/ -- Orna Therapeutics (Orna), a biotechnology company dedicated to engineering immune cells in vivo to treat autoimmune and oncology diseases, today announced new preclinical data supporting
More news about: Orna Therapeutics
Dec 06, 2025, 15:40 ET Zenocutuzumab-zbco (BIZENGRI®) Shows Durable Efficacy in Patients with Treatment-Naïve NRG1+NSCLC: Updated eNRGy Trial Results Presented at IASLC-ASCO NACLC
LEXINGTON, Mass., Dec. 6, 2025 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company, announced new data from a post hoc analysis of the Phase 2 eNRGy trial (NCT02912949) evaluating zenocutuzumab in patients with treatment-naïve
More news about: Partner Therapeutics, Inc.
Dec 06, 2025, 09:45 ET Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin's Lymphoma at the 2025 ASH Annual Meeting
supporting repeat dosing and eliminating the need for conventional ex vivo cell manufacturing.About Vivacta BioVivacta Bio is a biotechnology company dedicated to developing next-generation in vivo CAR-T therapies for cancer and autoimmune diseases. Leveraging innovations in T-cell–targeted
More news about: Vivacta Biotechnology Co., Ltd.
Dec 05, 2025, 18:00 ET Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
conditions of the stock option agreement covering the grant.About Nektar TherapeuticsNektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
Dec 05, 2025, 17:15 ET Blue Water Acquisition Corp. IV, Sponsored by Serial Entrepreneur Joseph Hernandez, Files $125Million IPO Registration Statement with the U.S. Securities and Exchange Commission
acquisition opportunity in any business, industry, sector or geographical location, the Company intends to focus on high-potential companies in the biotechnology, healthcare and technology sectors.BTIG, LLC is serving as the sole book-running manager of the offering.A registration statement
More news about: Blue Water Acquisition Corp. IV
Dec 05, 2025, 11:31 ET OCTO Skincare Launches at Milan Fashion Week 2025
PLANTUS, a Brazilian leader in biotechnology, and the sustainable sourcing of innovative, raw, and organic materials. Together, OCTO and PLANTUS abide by fair-trade and labor practices, and
More news about: Octo, Inc.
Dec 05, 2025, 11:16 ET Carisma Announces Delisting from Nasdaq and SEC Deregistration
the Company's ongoing pursuit of an orderly wind down of its operations.About Carisma TherapeuticsCarisma Therapeutics is a biotechnology company that was previously focused on applying its industry leading expertise in macrophage engineering to develop transformative therapies to
More news about: Carisma Therapeutics Inc.
Dec 05, 2025, 10:50 ET Life Sciences BPO Market is expected to generate a revenue of USD 481.8 Billion by 2032, Globally, at 7.50% CAGR: Verified Market Research®
Driver1. Rising R&D Costs and Increasing Demand for Operational EfficiencyPharmaceutical and biotechnology companies continue to experience rising R&D expenses driven by complex molecule development, regulatory scrutiny, and longer clinical timelines.To
More news about: Verified Market Research